home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

22 23 Next >

bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital

March 18, 2024

From bluebird bio, Inc.

Via Business Wire

Is Bluebird Bio Stock a Buy Now? ↗

March 13, 2024

Are you feeling brave?

Via The Motley Fool

bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy

March 11, 2024

From bluebird bio, Inc.

Via Business Wire

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

March 06, 2024

Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place

Via MarketBeat

Forecasting The Future: 6 Analyst Projections For bluebird bio ↗

March 05, 2024

Via Benzinga

(BLUE) - Analyzing bluebird bio's Short Interest ↗

February 29, 2024

Via Benzinga

Why Bluebird Bio Stock Dived Into the Red on Tuesday ↗

March 05, 2024

The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.

Via The Motley Fool

MarketBeat Week in Review – 2/26 - 3/1

March 02, 2024

As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest

Via MarketBeat

Topics Economy Stocks

bluebird bio Stock Signals Potential to be a Multi-bagger

February 29, 2024

Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do

Via MarketBeat

Topics Economy

Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗

February 27, 2024

Both companies are working on treatments for genetic disorders.

Via Investor's Business Daily

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 29, 2024

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Via Benzinga

bluebird bio: How to play LEAPS options for growth and income

February 27, 2024

Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT

Via MarketBeat

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 27, 2024

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Via Benzinga

bluebird bio stock is ripe for a 400% institutional short squeeze

February 27, 2024

Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in

Via MarketBeat

Topics Economy

Is CRISPR Therapeutics the NVIDIA of gene editing?

February 26, 2024

CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv

Via MarketBeat

Topics Artificial Intelligence

Gene therapy: Why does it cost millions for a single treatment?

February 15, 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.

Via MarketBeat

If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today ↗

January 27, 2024

The answer hardly inspires confidence.

Via The Motley Fool

Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule ↗

January 17, 2024

FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...

Via Benzinga

2 Red Flags for Bluebird Bio Stock ↗

January 10, 2024

The biotech's struggles may continue.

Via The Motley Fool

2 low-priced gene therapy stocks to speculate on

January 08, 2024

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe

Via MarketBeat

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook

January 08, 2024

From bluebird bio, Inc.

Via Business Wire

Better Risky Investment: Bluebird Bio vs. Shiba Inu ↗

January 03, 2024

Few investors dare to tread where the ice is known to be very thin.

Via The Motley Fool

bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From bluebird bio, Inc.

Via Business Wire

Should You Invest in Bluebird Bio Right Now? ↗

December 26, 2023

After two December share price crashes, there's no evident cure for Bluebird Bio's ills.

Via The Motley Fool

If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today ↗

December 24, 2023

Can things get better for this struggling stock?

Via The Motley Fool

1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗

December 23, 2023

The stock has been in the news lately.

Via The Motley Fool

3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 ↗

December 22, 2023

Doing a little math and doing a little extra research can make a big difference.

Via The Motley Fool

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? ↗

December 22, 2023

The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 21, 2023

Via Benzinga

S&P 500 Edges Lower; General Mills Cuts Sales Forecast ↗

December 20, 2023

U.S. stocks traded mixed toward the end of trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.07% to 37,586.02 while the NASDAQ rose 0.17% to 15,029.36. The S&P 500, however,...

Via Benzinga

Topics Stocks

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com